Published in Women's Health Weekly, March 30th, 2006
Now in a phase 2 clinical trial of MF101, Bionovo has begun recruiting participants to evaluate them for the treatment of menopausal symptoms. MF101 is a selective estrogen receptor modulator, unlike other available hormone therapies.
This second clinical trial of MF101 followed the initial trial conducted at the University of California, San Francisco under the auspices of Deborah...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly